Bernstein Liebhard LLP reminds ADMA Biologics, Inc. investors that the deadline to join a securities fraud class action lawsuit is August 10, 2026. The lawsuit, filed on behalf of investors who purchased or acquired ADMA securities between August 9, 2024 and March 25, 2026, alleges that the company and certain senior officers made materially false and misleading statements about its business operations, growth prospects, and financial stability, causing shares to trade at artificially inflated prices. Investors who suffered losses are encouraged to submit a form or contact Investor Relations Manager Peter Allocco at (212) 951-2030. Those wishing to serve as lead plaintiff must file papers by the deadline, though participation in any recovery does not require serving as lead plaintiff.
ADMA Biologics IncSecurities fraud class action lawsuit alleging false statements about business operations and financial stability.